Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864784 | 1.00 | KMT2A (0.45) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864782 | 1.00 | KMT2A (0.45) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864231 | 0.87 | MC4R (0.47) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864232 | 0.87 | MC4R (0.47) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864594 | 0.85 | KMT2A (0.42) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864596 | 0.85 | KMT2A (0.42) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864595 | 0.85 | KMT2A (0.42) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864982 | 0.84 | ROCK1 (0.45) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864980 | 0.84 | ROCK1 (0.45) | KMT2APABPC1SCN9AMC4RMAPK1 | |
| SCHEMBL864981 | 0.84 | ROCK1 (0.45) | KMT2APABPC1SCN9AMC4RMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | KMT2A 2799/4885PABPC1 4433/4885SCN9A 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.